Varivax

Pipeline

Status by Indication[3][1]

Competition

Competitive Landscape

237 competitors in Hepatitis

#DrugCompanyPhaseTrials

1

Actos

Takeda

Phase 3

42

Cysteine Hydrochloride

Novartis

Phase 3

33

Crestor

AstraZeneca

Phase 3

14

Deltasone

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

95

Aquasol E

NNational Eye Institute (NEI)

Phase 3

26

Amoxil

GGlobal Antibiotics Research and Development Partnership

Phase 3

17

Prevnar

GSK

Phase 3

18

Rimonabant

Sanofi

Phase 3

19

Hepatitis B Vaccine

Sanofi

Phase 3

110

Cenicriviroc

TTobira Therapeutics, Inc.

Phase 3

3Show 24 more competitors

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Clinical

Trials by Indication[1]

Immunogenicity14 trials

Safety, Tolerability, and Immunogenicity of a 3-dose Regimen of V114 in Healthy Infants (PNEU-PED-EU-2/V114-026)

Completed·Merck & Co.·Phase 3·NCT04016714·1,191 enrolled

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Recruiting·GGreen Cross Corporation·Phase 2·NCT05422508·230 enrolled

Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age

Completed·GSK·Phase 2·NCT00861744·1,259 enrolled

Show 11 more trials

Immunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines

Completed·SSinovac (Dalian) Vaccine Technology Co., Ltd.·Phase 3·NCT06314724·642 enrolled

Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT01702428·5,016 enrolled

Immunogenicity and Safety of NBP608 Compared to Varivax in Healthy Children 12 Months to 12 Years of Age

Completed·SSK Bioscience Co., Ltd.·Phase 3·NCT03114943·516 enrolled

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

Completed·GSK·Phase 3·NCT03621670·1,196 enrolled

Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)

Completed·Merck & Co.·Phase 3·NCT03893448·1,720 enrolled

Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life

Completed·GSK·Phase 3·NCT01681992·4,538 enrolled

The Evaluation of Immunogenicity and Safety of NBP608 in Healthy Children 12 Months to 12 Years of Age

Completed·SSK Chemicals Co., Ltd.·Phase 2·NCT03114982·152 enrolled

Safety and Immunogenicity Study of Hib-MenCY-TT Vaccine Compared to Licensed Hib Conjugate Vaccine

Completed·GSK·Phase 3·NCT00289783·4,441 enrolled

Evaluation of the Immunogenicity and Safety of VARIVAX™ in Healthy Russians (V210-058)

Completed·Merck & Co.·Phase 3·NCT03843632·150 enrolled

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Not yet recruiting·GGC Biopharma Corp·Phase 3·NCT07054099·474 enrolled

Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck & Co., Inc.'s MMR Vaccine in Healthy Children 12 to 15 Months of Age

Completed·GSK·Phase 3·NCT02184572·1,742 enrolled

Vaccine3 trials

Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Recruiting·Sanofi·Phase 3·NCT06824194·2,320 enrolled

Safety of Hib-MenCY-TT Vaccine Versus Licensed Hib Conjugate Vaccine, Given at 12 to 15 Months of Age.

Completed·GSK·Phase 3·NCT00345683·4,021 enrolled

Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06736041·1,714 enrolled

Varicella1 trial

SkyVaricella® (NBP608) Vaccine With Lower Potencies in Healthy Children Aged 12 Months to 12 Years

Not yet recruiting·SSK Bioscience Co., Ltd.·Phase 3·NCT07415252·780 enrolled

Vaccination1 trial

Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age

Active, not recruiting·Sanofi·Phase 3·NCT06824181·580 enrolled

Hepatitis1 trial

Immunogenicity & Safety of Hepatitis A Vaccine Co-admin With a Measles/Mumps/Rubella & a Varicella Vaccine in Children

Completed·GSK·Phase 3·NCT00197015·1,474 enrolled

7 more indications

Renal Transplant Recipients1 trial

Evaluation of the Safety of Varivax® in Pediatric Renal Transplant Recipients

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00005009·7 enrolled

Immune Response1 trial

Immune Responses to Two Dose Varivax +/- MMR-II

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00258726·105 enrolled

Adult1 trial

Safety Study of NBP608 in Healthy Adult Volunteers

Completed·SSK Chemicals Co., Ltd.·Phase 1·NCT03121638·150 enrolled

Vaccines1 trial

Hib-MenCY-TT Vaccine Study Compared to Licensed Hib and Meningococcal Serogroup C Conjugate Vaccines

Completed·GSK·Phase 2·NCT00134719·1,104 enrolled

Safety and Efficacy1 trial

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

Completed·GGreen Cross Corporation·Phase 1·NCT02367638·39 enrolled

Infants1 trial

A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)

Completed·Merck & Co.·Phase 3·NCT03620162·900 enrolled

Unspecified2 trials

Safety Study of a Refrigerator-stable Formulation of VARIVAX®

Completed·Merck & Co.·Phase 4·NCT00432731·500 enrolled

Re-examination Study For Varivax (V210-059 AM2)

Completed·Merck & Co.··NCT01062061·754 enrolled

Details

Drug Info

Related News